DeepMed Research

Western History Collection

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1890-01-01

Employees: 10K

Market Cap: -

Website: http://www.ou.edu

Clinical Trials

Effect of Gabapentin on Post-Operative Pain in Minimally Invasive Sacrocolpopexy

Early Phase 1

Completed

Conditions: Post Operative Pain

Interventions: Drug: Placebo
Drug: Gabapentin

First Posted Date: 2022-11-08

Last Posted Date: 2024-12-06

Lead Sponsor: University of Oklahoma

Target Recruit Count: 40

Registration Number: NCT05609682

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Behavioral Activation + Occupational Therapy: An Innovative Intervention for Empowered Self-Management of Multiple Chronic Conditions

Not Applicable

Recruiting

Conditions: Disability Physical
Multiple Chronic Conditions

Interventions: Behavioral: Enhanced Usual Care
Behavioral: Behavioral Activation + Occupational Therapy

First Posted Date: 2022-10-31

Last Posted Date: 2024-03-06

Lead Sponsor: University of Oklahoma

Target Recruit Count: 40

Registration Number: NCT05600465

Locations: 🇺🇸
OU Health Internal Medicine- Schusterman Clinic, Tulsa, Oklahoma, United States

Beta-Adrenergic Modulation of Drug Cue Reactivity

Phase 4

Recruiting

Conditions: Tobacco Use Disorder
Nicotine Dependence
Cigarette Smoking

Interventions: Drug: Propranolol
Drug: Placebo Propranolol
Drug: Nicotine Patch
Drug: Placebo Patch

First Posted Date: 2022-10-20

Last Posted Date: 2025-02-20

Lead Sponsor: University of Oklahoma

Target Recruit Count: 80

Registration Number: NCT05587361

Locations: 🇺🇸
Hardesty Center for Clinical Research and Neuroscience, Tulsa, Oklahoma, United States

Cognitive-Behavioral Therapy for Children With Nightmares as a Mediator of Suicide Risk (COMAA)

Not Applicable

Completed

Conditions: Nightmare

Interventions: Behavioral: Cognitive Behavioral Therapy

First Posted Date: 2022-10-20

Last Posted Date: 2023-06-22

Lead Sponsor: University of Oklahoma

Target Recruit Count: 58

Registration Number: NCT05588739

Locations: 🇺🇸
University of Tulsa, Tulsa, Oklahoma, United States
🇺🇸
University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, United States

Testing a Novel Smartphone Application for Smoking Cessation With the Oklahoma Helpline

Not Applicable

Recruiting

Conditions: Smoking Cessation

Interventions: Behavioral: Standard Helpline Care
Behavioral: OKquit

First Posted Date: 2022-09-14

Last Posted Date: 2025-01-30

Lead Sponsor: University of Oklahoma

Target Recruit Count: 500

Registration Number: NCT05539209

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

MC RCT - BPO vs Adapalene

Phase 3

Withdrawn

Conditions: Molluscum Contagiosum

Interventions: Drug: Adapalene Gel
Drug: Benzoyl peroxide

First Posted Date: 2022-09-13

Last Posted Date: 2024-03-06

Lead Sponsor: University of Oklahoma

Registration Number: NCT05536882

Locations: 🇺🇸
OU Health Department of Dermatology, Oklahoma City, Oklahoma, United States

The Oklahoma Parent-Child Assistance Program

Not Applicable

Recruiting

Conditions: Alcohol Use Complicating Pregnancy, Third Trimester
Substance Use Disorders
Alcohol Use Disorder (AUD)
Alcohol Use Complicating Pregnancy, First Trimester
Maternal Drugs Affecting Fetus
Alcohol Use Complicating Pregnancy, Unspecified Trimester
Fetal Alcohol Spectrum Disorders
Drug Use Complicating Pregnancy, Unspecified Trimester
Drug Use Complicating Pregnancy, Childbirth, and the Puerperium
Pregnancy Related

Interventions: Other: Parent-Child Assistance Program

First Posted Date: 2022-09-09

Last Posted Date: 2024-06-07

Lead Sponsor: University of Oklahoma

Target Recruit Count: 200

Registration Number: NCT05534568

Locations: 🇺🇸
Oklahoma City, Oklahoma City, Oklahoma, United States
🇺🇸
Tulsa, Tulsa, Oklahoma, United States

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2

Terminated

Conditions: Recurrent Endometrial Carcinoma
Recurrent Ovarian Carcinoma
ARID1A Gene Mutation

Interventions: Drug: Bevacizumab
Drug: Niraparib

First Posted Date: 2022-08-31

Last Posted Date: 2025-03-28

Lead Sponsor: University of Oklahoma

Target Recruit Count: 7

Registration Number: NCT05523440

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States

Digital Chest Tube Drainage System (Thopaz+) Versus Analog in Pediatric Patients

Not Applicable

Recruiting

Conditions: Air Leakage

Interventions: Device: Atrium Analog Device
Device: Madela THOPAZ Digital Device

First Posted Date: 2022-08-23

Last Posted Date: 2024-10-10

Lead Sponsor: University of Oklahoma

Target Recruit Count: 140

Registration Number: NCT05511987

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Phase 2

Recruiting

Conditions: Cervical Cancer
High Grade Serous Ovarian Cancer
Endometrioid Cancer
Mucinous Ovarian Cancer
Solid Tumor

Interventions: Drug: Avutometinib (VS-6766) + defactinib

First Posted Date: 2022-08-23

Last Posted Date: 2025-02-10

Lead Sponsor: University of Oklahoma

Target Recruit Count: 55

Registration Number: NCT05512208

Locations: 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
AdventHealth, Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy